[4].XY Yang, JC Allen, EJ Aslim, et al. Patient-Reported outcomes of a phase II Neoadjuvant Apalutamide (ARN-509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer (NEAR) trial...
[8] Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, ...
“高危”前列腺癌的分类 Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014 Jun;11(6):308-23. doi: 10.1038/nrclinonc.2014.68. Epub 2014 May 20. PMID: 24840073; PMCID: PMC4508854. 大约15%的前列腺癌患者被诊断出患...
High-risk prostate cancer with Gleason score 8-10 and PSA level 15 ng/ml treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011;81:992-6.Fang LC, Merrick GS, Butler WM, Galbreath RW, Murray BC, Reed JL, et al.: High-risk prostate cancer with Gleason score...
[8] Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.[J].Lancet Oncol.2019 May;20(5):686...
[6].Fizazi K, et al. Lancet Oncol. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. 2019; 20(5):686-700. ...
1,2However, the observed relative reduction in prostate cancer mortality came alongwith a considerable risk of overdiagnosisand overtreatment. For this reason, major reviews of the evidence for PSA screening have concluded that itcannot be recommended. The influentialUS Preventive Services Task Force...
Stanczyk FZ, Skinner EC, Mertes S, Spahn MF, Lobo RA & Ross RK (1996) Alterations in circulating levels of androgens and PSA during treatment with Finasteride in men at high risk for prostate cancer. In Hormonal Carcinogenesis II, pp. 404- 407 [JJ Li, SA Li, J Gustafsson, S Nandi ...
Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports the
PSA levels appear to be more predictive of three year prostate cancer risk in African-American men compared with Caucasian men with a family history of prostate cancer, according to a paper published in Cancer Prevention Research, a journal of the Americ